SG11201408113QA - Mutational analysis of plasma dna for cancer detection - Google Patents

Mutational analysis of plasma dna for cancer detection

Info

Publication number
SG11201408113QA
SG11201408113QA SG11201408113QA SG11201408113QA SG11201408113QA SG 11201408113Q A SG11201408113Q A SG 11201408113QA SG 11201408113Q A SG11201408113Q A SG 11201408113QA SG 11201408113Q A SG11201408113Q A SG 11201408113QA SG 11201408113Q A SG11201408113Q A SG 11201408113QA
Authority
SG
Singapore
Prior art keywords
lllll
international
hong kong
sar
llll
Prior art date
Application number
SG11201408113QA
Inventor
Yuk-Ming Dennis Lo
Kwan Chee Chan
Wai Kwun Rossa Chiu
Peiyong Jiang
Original Assignee
Univ Hong Kong Chinese
Wai Kwun Rossa Chiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Chinese, Wai Kwun Rossa Chiu filed Critical Univ Hong Kong Chinese
Publication of SG11201408113QA publication Critical patent/SG11201408113QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C12Q2539/107—Representational Difference Analysis [RDA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 December 2013 (27.12.2013) WIPOIPCT (10) International Publication Number WO 2013/190441 A3 (51) International Patent Classification: C12Q 1/68 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/IB2013/054898 14 June 2013 (14.06.2013) English English (30) Priority Data: 61/662,878 61/682,725 61/695,795 61/711,172 13/801,748 21 June 2012 (21.06.2012) US 13 August 2012 (13.08.2012) US 31 August 2012 (31.08.2012) US 8 October 2012 (08.10.2012) US 13 March 2013 (13.03.2013) US (71) Applicant: THE CHINESE UNIVERSITY OF HONG KONG [CN/CN]; Knowledge Transfer Office, Shatin, New Territories, Hong Kong, SAR (CN). (72) Inventor; and (71) Applicant CHIU, : Wai, Kwun, Rossa [AU/CN]; House 31, Double Haven, 52 Ma Lok Path, Shatin, New Territor­ ies, Hong Kong (CN). (72) Inventors: LO, Yuk-Ming, Dennis; 4th Floor, 7King Tak Street, Homantin Kowloon, Hong Kong (SAR) (CN). CHAN, Kwan, Chee; Flat A, 13/F, Block 34, Broadway Street, Mei Foo Sun Chuen, Kowloon, Hong Kong SAR (CN). JIANG, Peiyong; Flat 7. 1st floor of Block B, Kwong Lam Court, Nos 62-66 Siu Lek Yuen Road, Shatin New Territories, Hong Kong SAR (CN). (74) Agent: GRIFFITH HACK & CO; Level 10, 161 Collins Street, Melbourne, Victoria 3000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, [Continued on next page] (54) Title: MUTATIONAL ANALYSIS OF PLASMA DNA FOR CANCER DETECTION Receive one or mare sequenced tags for each of a plurality of D.N A fragTaeDts m a biological >amaic of the ss;bjecl genomic positions for tlie ^tqu-Jiiced i; (57) Abstract: A frequency of somatic mutations in biological sample a (e.g., plasma or serum) of a subject undergoing screening or monitoring for cancer, can be compared with that in the constitutional DNA of the same subject. A parameter can derived from these frequencies and used to determine a classi­ fication of a level of cancer. False positives can be filtered out by requiring any variant locus to have at least a specified number of variant sequence reads (tags), thereby providing a more accurate parameter. The relative frequencies for different variant loci can be analyzed to determine level of heterogeneity a of tumors in a patient. Determine a first n N sequence h? rhe co a sequence variant retain s tutiona^ genome WO 2013/190441 A3 I lllll llllllll II llllll III lllll lllll III III III lllll lllll lllll lllll llll lllll lllllll llll llll llll EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 27 February 2014
SG11201408113QA 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection SG11201408113QA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261662878P 2012-06-21 2012-06-21
US201261682725P 2012-08-13 2012-08-13
US201261695795P 2012-08-31 2012-08-31
US201261711172P 2012-10-08 2012-10-08
US13/801,748 US11261494B2 (en) 2012-06-21 2013-03-13 Method of measuring a fractional concentration of tumor DNA
PCT/IB2013/054898 WO2013190441A2 (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Publications (1)

Publication Number Publication Date
SG11201408113QA true SG11201408113QA (en) 2015-01-29

Family

ID=52274459

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201408113QA SG11201408113QA (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection
SG10201808217WA SG10201808217WA (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201808217WA SG10201808217WA (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Country Status (19)

Country Link
US (3) US11261494B2 (en)
EP (3) EP3456843B1 (en)
JP (4) JP6371280B2 (en)
KR (5) KR101884909B1 (en)
CN (3) CN113151474A (en)
AU (4) AU2013278994C1 (en)
CA (2) CA3080937A1 (en)
DK (2) DK3456843T3 (en)
EA (2) EA202092900A3 (en)
ES (2) ES2894479T3 (en)
HK (3) HK1204013A1 (en)
HU (1) HUE056915T2 (en)
IL (5) IL311127A (en)
MX (3) MX360264B (en)
PT (1) PT3456843T (en)
SG (2) SG11201408113QA (en)
TW (4) TWI636255B (en)
WO (1) WO2013190441A2 (en)
ZA (1) ZA201409281B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168370B2 (en) 2015-02-10 2021-11-09 The Chinese University Of Hong Kong Detecting mutations for cancer screening

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
KR20130113447A (en) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Direct capture, amplification and sequencing of target dna using immobilized primers
EP3225697A3 (en) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
EP3591073B1 (en) 2012-09-04 2021-12-01 Guardant Health, Inc. Methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
CN113337604A (en) 2013-03-15 2021-09-03 莱兰斯坦福初级大学评议会 Identification and use of circulating nucleic acid tumor markers
US9822408B2 (en) 2013-03-15 2017-11-21 Nugen Technologies, Inc. Sequential sequencing
CN105849264B (en) 2013-11-13 2019-09-27 纽亘技术公司 For identifying the composition and method that repeat sequencing reading
EP3524694B1 (en) 2013-12-28 2020-07-15 Guardant Health, Inc. Methods and systems for detecting genetic variants
RU2717641C2 (en) * 2014-04-21 2020-03-24 Натера, Инк. Detection of mutations and ploidy in chromosomal segments
WO2016008451A1 (en) 2014-07-18 2016-01-21 The Chinese University Of Hong Kong Methylation pattern analysis of tissues in dna mixture
KR20220127359A (en) * 2014-07-25 2022-09-19 유니버시티 오브 워싱톤 Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
EP3177740B1 (en) * 2014-08-06 2021-01-13 Nugen Technologies, Inc. Digital measurements from targeted sequencing
US11279979B2 (en) * 2014-08-07 2022-03-22 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
ES2925014T3 (en) 2014-09-12 2022-10-13 Univ Leland Stanford Junior Identification and use of circulating nucleic acids
CA2967447A1 (en) * 2014-12-05 2016-06-09 Foundation Medicine, Inc. Multigene analysis of tumor samples
CN114181997A (en) 2014-12-12 2022-03-15 维里纳塔健康股份有限公司 Determination of copy number variation using cell-free DNA fragment size
CA2972433A1 (en) * 2014-12-31 2016-07-07 Guardant Health, Inc. Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
JP6995625B2 (en) * 2015-05-01 2022-01-14 ガーダント ヘルス， インコーポレイテッド Diagnostic method
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
CN104894268B (en) * 2015-06-05 2018-02-09 上海美吉生物医药科技有限公司 The method and its application of the DNA concentration of Apoptosis are derived from quantitative sample
US20180188258A1 (en) * 2015-07-01 2018-07-05 Keio University Marker for heterogeneity of cancer tissue, and use thereof
JP2017016665A (en) * 2015-07-03 2017-01-19 国立大学法人東北大学 Method for selecting variation information from sequence data, system, and computer program
CN108138233B (en) 2015-07-20 2022-08-26 香港中文大学 Methylation Pattern analysis of haplotypes of tissues in DNA mixtures
TWI730973B (en) 2015-07-23 2021-06-21 香港中文大學 Analysis of fragmentation patterns of cell-free dna
MY188348A (en) * 2015-08-12 2021-12-02 Univ Hong Kong Chinese Single-molecule sequencing of plasma dna
WO2017035400A1 (en) 2015-08-25 2017-03-02 Nantomics, Llc Systems and methods for genetic analysis of metastases
WO2017106768A1 (en) 2015-12-17 2017-06-22 Guardant Health, Inc. Methods to determine tumor gene copy number by analysis of cell-free dna
US11335463B2 (en) * 2016-02-02 2022-05-17 Guardant Health, Inc. Cancer evolution detection and diagnostic
US10095831B2 (en) 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
KR101810528B1 (en) * 2016-03-29 2017-12-21 한국과학기술원 Method and apparatus for measuring functional recurrence of cancer somatic mutations in noncoding regions
WO2017181146A1 (en) 2016-04-14 2017-10-19 Guardant Health, Inc. Methods for early detection of cancer
GB2555765A (en) * 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
CN105969656B (en) * 2016-05-13 2019-09-10 万康源(天津)基因科技有限公司 A kind of unicellular exon sequencing tumour somatic mutation detection and analysis platform
CN105969856B (en) * 2016-05-13 2019-11-12 万康源(天津)基因科技有限公司 A kind of unicellular exon sequencing tumour somatic mutation detection method
CN106355045B (en) * 2016-08-30 2019-03-15 天津诺禾致源生物信息科技有限公司 A kind of method and device based on amplification second filial sequencing small fragment insertion and deletion detection
AU2017336153B2 (en) * 2016-09-30 2023-07-13 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
MY195527A (en) 2016-10-24 2023-01-30 Grail Inc Methods And Systems For Tumor Detection
GB201618485D0 (en) * 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
CN114774520A (en) * 2016-11-17 2022-07-22 领星生物科技（上海）有限公司 System and method for detecting tumor development
JP2020503003A (en) 2016-11-30 2020-01-30 ザ チャイニーズ ユニバーシティ オブ ホンコン Analysis of cell-free DNA in urine and other samples
WO2018106884A1 (en) * 2016-12-08 2018-06-14 Life Technologies Corporation Methods for detecting mutation load from a tumor sample
CN106874710A (en) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 A kind of device for using tumour FFPE pattern detection somatic mutations
CN106845153A (en) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 A kind of device for using Circulating tumor DNA pattern detection somatic mutation
MY197535A (en) 2017-01-25 2023-06-21 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
US11342047B2 (en) * 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant
EP3625341A4 (en) * 2017-05-16 2021-05-19 Guardant Health, Inc. Identification of somatic or germline origin for cell-free dna
KR102145417B1 (en) * 2017-05-24 2020-08-19 지니너스 주식회사 Method for generating distribution of background allele frequency for sequencing data obtained from cell-free nucleic acid and method for detecting mutation from cell-free nucleic acid using the same
CA3070898A1 (en) 2017-07-26 2019-01-31 The Chinese University Of Hong Kong Enhancement of cancer screening using cell-free viral nucleic acids
WO2019055835A1 (en) * 2017-09-15 2019-03-21 The Regents Of The University Of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
CN111357054A (en) * 2017-09-20 2020-06-30 夸登特健康公司 Methods and systems for differentiating between somatic and germline variations
KR20200044123A (en) * 2017-10-10 2020-04-28 난토믹스, 엘엘씨 COMPREHENSIVE GENOMIC TRANSCRIPTOMIC TUMOR-NORMAL GENE PANEL ANALYSIS FOR ENHANCED PRECISION IN PATIENTS WITH CANCER
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
WO2019090156A1 (en) * 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
WO2019108972A1 (en) * 2017-11-30 2019-06-06 Illumina, Inc. Validation methods and systems for sequence variant calls
US20190249229A1 (en) * 2018-02-12 2019-08-15 Nant Holdings Ip, Llc Bam signatures from liquid and solid tumors and uses therefor
CN112218957A (en) * 2018-04-16 2021-01-12 格里尔公司 Systems and methods for determining tumor fraction in cell-free nucleic acids
CA3098321A1 (en) 2018-06-01 2019-12-05 Grail, Inc. Convolutional neural network systems and methods for data classification
EP3802878A1 (en) * 2018-06-04 2021-04-14 Guardant Health, Inc. Methods and systems for determining the cellular origin of cell-free nucleic acids
EP3827100A2 (en) * 2018-07-23 2021-06-02 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
EP3874066A1 (en) * 2018-11-01 2021-09-08 Illumina, Inc. Methods and compositions for somatic variant detection
US11581062B2 (en) 2018-12-10 2023-02-14 Grail, Llc Systems and methods for classifying patients with respect to multiple cancer classes
CN113366122B (en) 2018-12-19 2024-01-12 香港中文大学 Free DNA end characterization
CA3122109A1 (en) * 2018-12-21 2020-06-25 Grail, Inc. Systems and methods for using fragment lengths as a predictor of cancer
CN109686414A (en) * 2018-12-28 2019-04-26 陈洪亮 It is only used for the choosing method of the special DNA methylation assay Sites Combination of Hepatocarcinoma screening
CN109616198A (en) * 2018-12-28 2019-04-12 陈洪亮 It is only used for the choosing method of the special DNA methylation assay Sites Combination of the single cancer kind screening of liver cancer
CN109817279B (en) * 2019-01-18 2022-11-04 臻悦生物科技江苏有限公司 Detection method and device for tumor mutation load, storage medium and processor
KR102381252B1 (en) * 2019-02-19 2022-04-01 주식회사 녹십자지놈 Method for Prognosing Hepatic Cancer Patients Based on Circulating Cell Free DNA
CN109841265B (en) * 2019-02-22 2021-09-21 清华大学 Method and system for determining tissue source of plasma free nucleic acid molecules by using fragmentation mode and application
CN109920480B (en) * 2019-03-14 2020-02-21 深圳市海普洛斯生物科技有限公司 Method and device for correcting high-throughput sequencing data
CN111755075B (en) * 2019-03-28 2023-09-29 深圳华大生命科学研究院 Method for filtering sequence pollution among high-throughput sequencing samples of immune repertoire
CA3139535A1 (en) * 2019-05-17 2020-11-26 Ultima Genomics, Inc. Methods and systems for detecting residual disease
CN111223525A (en) * 2020-01-07 2020-06-02 广州基迪奥生物科技有限公司 Tumor exon sequencing data analysis method
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
WO2023278524A1 (en) * 2021-06-30 2023-01-05 Memorial Sloan-Kettering Cancer Center Detection of somatic mutational signatures from whole genome sequencing of cell-free dna
KR20230085239A (en) * 2021-12-06 2023-06-14 주식회사 지씨지놈 Method for Prognosing Breast Cancer Patients Based on Circulating Cell Free DNA
CN115064212B (en) * 2022-06-24 2023-03-14 哈尔滨星云生物信息技术开发有限公司 WGS (generalized Gaussian mixture distribution) data-based method for identifying tumor specific mutation of population in preset area
WO2024003936A1 (en) 2022-06-29 2024-01-04 Raman Govindarajan Method for detecting cancer susceptibility, early detection and predicting cancer behaviour
CN117012274B (en) * 2023-10-07 2024-01-16 北京智因东方转化医学研究中心有限公司 Device for identifying gene deletion based on high-throughput sequencing

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039353D1 (en) 1999-04-02 2008-08-14 Corixa Corp COMPOUNDS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
EP1468104A4 (en) 2002-01-18 2006-02-01 Genzyme Corp Methods for fetal dna detection and allele quantitation
EP2292787B1 (en) 2002-05-10 2017-03-22 City of Hope Pyrophosphorolysis activated polymerization (PAP)
US7704687B2 (en) 2002-11-15 2010-04-27 The Johns Hopkins University Digital karyotyping
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
US8394582B2 (en) 2003-03-05 2013-03-12 Genetic Technologies, Inc Identification of fetal DNA and fetal cell markers in maternal plasma or serum
PL201608B1 (en) 2003-06-13 2009-04-30 Cezary Cybulski Method and set designed for detection of high genetic predisposition for prostate gland cancer as well as use of germinal change within the NBS1 gene
DE60328193D1 (en) 2003-10-16 2009-08-13 Sequenom Inc Non-invasive detection of fetal genetic traits
EP1751306A1 (en) 2004-04-30 2007-02-14 Yale University Methods and compositions for cancer diagnosis
AU2006224971B2 (en) * 2005-03-18 2009-07-02 Boston University A method for the detection of chromosomal aneuploidies
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
PT2385143T (en) 2006-02-02 2016-10-18 Univ Leland Stanford Junior Non-invasive fetal genetic screening by digital analysis
ATE508209T1 (en) 2006-02-28 2011-05-15 Univ Louisville Res Found DETECTION OF CHROMOSOME ABNORMALITIES IN THE FETUS USING TANDEM SINGLE NUCLEOTIDE POLYMORPHISMS
EA010571B1 (en) 2006-08-15 2008-10-30 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Method for diagnosis of non-small cell carcinoma of lung and a kit therefor
WO2008146309A2 (en) 2007-05-25 2008-12-04 Decode Genetics Ehf. Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP3067807A1 (en) 2007-07-23 2016-09-14 The Chinese University of Hong Kong Diagnosing fetal chromosomal aneuploidy using genomic sequencing
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
EP2952589B1 (en) * 2008-09-20 2018-02-14 The Board of Trustees of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US20100136560A1 (en) 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
US20120021428A1 (en) 2009-03-31 2012-01-26 Marcus Otte Method for diagnosis of cancer and monitoring of cancer treatments
WO2011038507A1 (en) 2009-10-02 2011-04-07 Centre For Addiction And Mental Health Method for analysis of dna methylation profiles of cell-free circulating dna in bodily fluids
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
AU2010315037B9 (en) 2009-11-05 2015-04-23 Sequenom, Inc. Fetal genomic analysis from a maternal biological sample
EA034241B1 (en) 2009-11-06 2020-01-21 Те Чайниз Юниверсити Ов Гонконг Method for performing prenatal diagnosis of a sequence imbalance
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
AU2011207544A1 (en) 2010-01-19 2012-09-06 Verinata Health, Inc. Identification of polymorphic sequences in mixtures of genomic DNA by whole genome sequencing
EP2883965B8 (en) 2010-01-19 2018-06-27 Verinata Health, Inc Method for determining copy number variations
US20130210645A1 (en) 2010-02-18 2013-08-15 The Johns Hopkins University Personalized tumor biomarkers
EP2426217A1 (en) 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
MX349568B (en) 2010-11-30 2017-08-03 Univ Hong Kong Chinese Detection of genetic or molecular aberrations associated with cancer.
KR101974492B1 (en) 2011-07-26 2019-05-02 베리나타 헬스, 인코포레이티드 Method for determining the presence or absence of different aneuploidies in a sample
DK2764459T3 (en) 2011-10-06 2021-08-23 Sequenom Inc METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS
WO2013086352A1 (en) 2011-12-07 2013-06-13 Chronix Biomedical Prostate cancer associated circulating nucleic acid biomarkers
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
WO2013138510A1 (en) 2012-03-13 2013-09-19 Patel Abhijit Ajit Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
EP3591073B1 (en) 2012-09-04 2021-12-01 Guardant Health, Inc. Methods to detect rare mutations and copy number variation
SG11201506660RA (en) 2013-02-21 2015-09-29 Toma Biosciences Inc Methods, compositions, and kits for nucleic acid analysis
CA3156663A1 (en) 2013-03-15 2014-09-18 Verinata Health, Inc. Generating cell-free dna libraries directly from blood
US10174375B2 (en) 2013-09-20 2019-01-08 The Chinese University Of Hong Kong Sequencing analysis of circulating DNA to detect and monitor autoimmune diseases
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
KR20220127359A (en) 2014-07-25 2022-09-19 유니버시티 오브 워싱톤 Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168370B2 (en) 2015-02-10 2021-11-09 The Chinese University Of Hong Kong Detecting mutations for cancer screening

Also Published As

Publication number Publication date
KR20180088922A (en) 2018-08-07
EA202092900A3 (en) 2021-06-30
KR20150032708A (en) 2015-03-27
CN113151474A (en) 2021-07-23
KR101884909B1 (en) 2018-08-02
IL311127A (en) 2024-04-01
IL268645A (en) 2019-10-31
EP3456843B1 (en) 2021-07-28
EP3919627A1 (en) 2021-12-08
IL278867B1 (en) 2023-01-01
AU2013278994A1 (en) 2015-01-29
HK1204013A1 (en) 2015-11-06
JP6930948B2 (en) 2021-09-01
JP2018191640A (en) 2018-12-06
AU2013278994B2 (en) 2017-04-06
MX2023001154A (en) 2023-02-22
US20180202003A1 (en) 2018-07-19
IL298810B1 (en) 2024-04-01
JP2021191280A (en) 2021-12-16
MX360264B (en) 2018-10-26
JP6371280B2 (en) 2018-08-08
TW202328458A (en) 2023-07-16
KR102237923B1 (en) 2021-04-08
ES2687847T3 (en) 2018-10-29
EP2864501B1 (en) 2018-08-08
MX2018013085A (en) 2021-11-16
AU2017204558A1 (en) 2017-07-27
AU2020200122B2 (en) 2022-05-19
IL235967A0 (en) 2015-01-29
HUE056915T2 (en) 2022-03-28
EA202092900A2 (en) 2021-03-31
CA2876327A1 (en) 2013-12-27
CA2876327C (en) 2020-09-29
IL278867A (en) 2021-01-31
IL278867B2 (en) 2023-05-01
HK1246830A1 (en) 2018-09-14
AU2017204558B2 (en) 2019-10-10
MX2014016058A (en) 2015-04-10
JP2015527057A (en) 2015-09-17
WO2013190441A2 (en) 2013-12-27
US20140100121A1 (en) 2014-04-10
KR102096611B1 (en) 2020-04-02
EA037292B1 (en) 2021-03-05
KR102375645B1 (en) 2022-03-17
AU2022209294A1 (en) 2022-08-25
KR102521842B1 (en) 2023-04-14
US20190264291A1 (en) 2019-08-29
IL298810A (en) 2023-02-01
CN107779506A (en) 2018-03-09
CN104662168B (en) 2017-12-05
JP7408161B2 (en) 2024-01-05
DK2864501T3 (en) 2018-11-05
TW201403066A (en) 2014-01-16
US11261494B2 (en) 2022-03-01
KR20220038181A (en) 2022-03-25
CN107779506B (en) 2022-07-15
AU2020200122A1 (en) 2020-01-30
ES2894479T3 (en) 2022-02-14
TWI786428B (en) 2022-12-11
PT3456843T (en) 2021-10-26
WO2013190441A3 (en) 2014-02-27
EP3456843A1 (en) 2019-03-20
KR20210040464A (en) 2021-04-13
HK1205533A1 (en) 2015-12-18
JP2024026360A (en) 2024-02-28
EP2864501A2 (en) 2015-04-29
CN104662168A (en) 2015-05-27
EP2864501A4 (en) 2016-03-16
TWI803505B (en) 2023-06-01
ZA201409281B (en) 2017-08-30
KR20230052998A (en) 2023-04-20
IL235967B (en) 2019-09-26
TW202122796A (en) 2021-06-16
AU2013278994C1 (en) 2019-12-12
EA201500027A1 (en) 2015-05-29
DK3456843T3 (en) 2021-10-25
SG10201808217WA (en) 2018-10-30
CA3080937A1 (en) 2013-12-27
TWI636255B (en) 2018-09-21
KR20200035507A (en) 2020-04-03
TW201920952A (en) 2019-06-01

Similar Documents

Publication Publication Date Title
SG11201408113QA (en) Mutational analysis of plasma dna for cancer detection
SG11201408002TA (en) Multi-parameter diabetes risk evaluations
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201903509QA (en) Methods and systems for tumor detection
SG11201806595UA (en) Using cell-free dna fragment size to determine copy number variations
SG11201903158RA (en) Methods for cell label classification
SG11201909205YA (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201407668XA (en) Method and device for detecting an analyte in a body fluid
SG11201803666WA (en) Single image detection
SG11201908240YA (en) Methods for evaluating tumor cell spheroids using 3d microfluidic cell culture device
SG11201810694WA (en) Use of biomarkers in determining susceptibility to disease treatment
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201805119QA (en) Methods to determine tumor gene copy number by analysis of cell-free dna
SG11201901371XA (en) Methods for the detection of genomic copy changes in dna samples
SG11201903346QA (en) Gestational age assessment by methylation and size profiling of maternal plasma dna
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201809317VA (en) Methods for classifying patients with a solid cancer
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201407702XA (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
SG11201805906WA (en) Diagnostic and prognostic methods for cardiovascular diseases and events
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201407660SA (en) Systems and methods for detection of particles in a beneficial agent